US EditionSerina using $5M to develop SER-252 for advanced Parkinson's
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Serina using $5M to develop SER-252 for advanced Parkinson's
Serina Therapeutics will use $5 million in new funding to further develop SER-252 (POZ-apomorphine) as a treatment for advanced Parkinson’s disease, with a Phase 1 clinical study now expected by the end of the year. The company secured the financing from shareholders to support clinical testing of SER-252, its lead treatment candidate, according to a Serina press release. The trial is planned for launch in the fourth quarter, or within the last …
Integrated Clinical and Multidisciplinary Parkinson's Care (831) – Australian College of Nursing
MicrocredentialIntegrated Clinical and Multidisciplinary Parkinson's Care.dt-breadcrumbs-id-dfe33a98e7684e2aef97a4801d848f4e .breadcrumbs { display: inline-block; margin: 0; padding: 2px 10px 2px 10px; border: 0px solid ; border-radius: 0px; } .dt-breadcrumbs-id-dfe33a98e7684e2aef97a4801d848f4e .breadcrumbs * { color: #ffffff; } You are here:Home On this page: Overview | Scope of future study | Learning outcomes | Course structure | Ent…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
